Biopharmaceutical Company Announces Presents Preclinical Data For Netherton Syndrome Treatment
Azitra, Inc. Announces Breakthrough in Netherton Syndrome Treatment with ATR-12.
Disclaimer: The information provided in this article is for educational purposes only and is based on data available as of the last update. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions…